Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Preferred Shares (2016 - 2019)

Sanara MedTech's Preferred Shares history spans 4 years, with the latest figure at $11.4 million for Q4 2019.

  • For Q4 2019, Preferred Shares changed 0.0% year-over-year to $11.4 million; the TTM value through Dec 2019 reached $11.4 million, changed 0.0%, while the annual FY2019 figure was $11.4 million, 0.0% changed from the prior year.
  • Preferred Shares reached $11.4 million in Q4 2019 per SMTI's latest filing, roughly flat from $11.4 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $11.4 million in Q4 2018 to a low of $835020.0 in Q1 2016.
  • Average Preferred Shares over 4 years is $7.4 million, with a median of $11.4 million recorded in 2018.
  • Peak YoY movement for Preferred Shares: dropped 0.1% in 2017, then surged 1228.66% in 2018.
  • A 4-year view of Preferred Shares shows it stood at $856460.0 in 2016, then dropped by 0.1% to $855610.0 in 2017, then soared by 1228.66% to $11.4 million in 2018, then changed by 0.0% to $11.4 million in 2019.
  • Per Business Quant, the three most recent readings for SMTI's Preferred Shares are $11.4 million (Q4 2019), $11.4 million (Q3 2019), and $11.4 million (Q2 2019).